nbd

pGlu-K(-NBD)-Q-R-L-G-N-Q-W-A-V-G-H-L-M-N is a peptides

NBD-556 is a small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

NBD-10007 is an inhibitor of HIV-1 entry.

Alprenolol-nbd is a fluorescent beta-adrenoceptor probe that binds irreversibly to beta-adrenoceptors and non-receptor binding sites.

A cell-permeable synthetic peptide NEMO-binding domain peptide (NBD peptide) corresponding to the NEMO amino-terminal alpha-helical region is shown to block TNF-alpha-induced NF-kB activation. The interaction of IKγNEMO with the IKK complex is vital for t

IKKγ NBD Inhibitory Peptide acetate is a NEMO-binding domain peptide (NBD peptide) acetate corresponding to the NEMO amino-terminal alpha-helical region. IKKγ NBD Inhibitory Peptide acetate is shown to block TNF-alpha-induced NF-kB activation.

NBD-11021 is an inhibitor that prevents HIV from entering cells.

NBD-557 is a potential inhibitor of HIV-1 (Human Immunodeficiency Virus 1).

NBD-125 (B-12) is a berberine analogue. NBD-125 is an RXRα activator. The IC50 value of NBD-125 in KM12C cell is 31.10 μM [1].

NBD-14270 is a potent HIV-1 entry antagonist that acts on 50 strains of HIV-1 pseudotyped virus (IC50: 89 nM). nBD-14270 is a pyridine analogue with low cytotoxicity (CC50>100 μM). nBD-14270 binds HIV-1 gp120 and exhibits significant antiviral activity (EC50<200 nM). EC50<200 nM).

NBD-14189 is a potent HIV-1 entry antagonist that acts against the HIV-1HXB2 pseudovirus (IC50: 89 nM). NBD-14189 binds to HIV-1 gp120 and exhibits a strong antiviral effect (EC50 < 200 nM).

IKKγ NBD Inhibitory Peptide TFA is a specific NF-κB inhibitor that hinders the interaction between the IKKγ/NEMO-binding domain (NBD) and IKKα and IKKβ, effectively preventing TNF-α-induced NF-κB activation. It has been demonstrated to significantly suppress inflammation and improve neurological deficits induced by cerebral ischemia [1] [2] [3].

NBD-LLLLpY is a peptide synthesized enzymatically within the nucleus to selectively target and eliminate human induced pluripotent stem cells (hiPSCs).

CTP-NBD is a cell-permeable, specific inhibitor of the NFκB peptide, which has been utilized in studies of colitis [1] [2].

C-6 NBD-dihydro-Ceramide, a biologically active, fluorescent analog of short-chain ceramides, features membrane permeability.

NBD peptide inhibits the NF-κB signaling pathway by preventing the binding of the NEMO-IKK complex. It exhibits anti-inflammatory activity by blocking the production of pro-inflammatory cytokines. Additionally, NBD peptide demonstrates immunosuppressive effects through the regulation of immune cells. It enhances transmembrane capacity by conjugating with the cell-penetrating peptide HIV-TAT.

NBD-2 is an inhibitor targeting the NEMO-IKKα/β interaction within the NF-κB signaling pathway. It can specifically suppress the canonical NF-κB signaling both in vitro and in vivo, thereby reducing the inflammatory response in acute lung injury (ALI) induced by lipopolysaccharide (LPS). NBD-2 demonstrates significant anti-inflammatory activity and is applicable for research on diseases related to the NF-κB signaling pathway, such as autoimmune disorders and cancer.

25-NBD Cholest-4-en-3-one is a type of sterol.

22-NBD 25-hydroxycholesterol is a sterol.

NBD AA is a type of arachidonyl ethanolamide.

NBD-09027 is an inhibitor of HIV-1 entry.

Bz-Dab(nbd)-ala-trp-phe-pro-pro-nle-NH2 is a fluorescent NK2 antagonist.

FTY720, an immune modulator, down-regulates sphingosine-1-phosphate (S1P) receptors, enhances the activity of sphingosine transporter Abcb1 and leukotriene C4 transporter Abcc1, and inhibits cytosolic phospholipase A2 activity. Its efficacy relies on in vivo phosphorylation by sphingosine kinases, resulting in FTY720-phosphate which also down-regulates S1P receptors. NBD-FTY720, a fluorescently-labeled analog of FTY720, retains the hydroxy methyl side chain targeted for phosphorylation, suggesting potential phosphorylation in vivo.

Diacylglycerols (DAG) are generated through the hydrolysis of membrane phospholipids and function as lipid second messengers by activating protein kinase C (PKC) and modulating cell growth and apoptosis. Additionally, they act as precursors for DAG kinases in the synthesis of phosphatidic acid, a crucial lipid messenger. The compound 1-NBD-decanoyl-2-decanoyl-sn-glycerol incorporates a nitrobenzoxadiazole (NBD) fluorophore at the ω-end of its terminal decanoyl chain, using the structure of 1,2-didecanoyl-sn-glycerol as a model for diacylglycerol. This molecule is expected to exhibit excitation and emission peaks at roughly 470/541 nm, paralleling those of various NBD-labeled phospholipids. Fluorescently labeled lipids, such as this, are instrumental in exploring their interactions with proteins, their uptake by cells and liposomes, and in developing assays for lipid metabolism research.